Skip to main content

Advertisement

SpringerLink
Log in

A Review of Human Pluripotent Stem Cell-Derived Cardiomyocytes for High-Throughput Drug Discovery, Cardiotoxicity Screening, and Publication Standards

  • Published:
Journal of Cardiovascular Translational Research Aims and scope Submit manuscript

Abstract

Drug attrition rates have increased in past years, resulting in growing costs for the pharmaceutical industry and consumers. The reasons for this include the lack of in vitro models that correlate with clinical results and poor preclinical toxicity screening assays. The in vitro production of human cardiac progenitor cells and cardiomyocytes from human pluripotent stem cells provides an amenable source of cells for applications in drug discovery, disease modeling, regenerative medicine, and cardiotoxicity screening. In addition, the ability to derive human-induced pluripotent stem cells from somatic tissues, combined with current high-throughput screening and pharmacogenomics, may help realize the use of these cells to fulfill the potential of personalized medicine. In this review, we discuss the use of pluripotent stem cell-derived cardiomyocytes for drug discovery and cardiotoxicity screening, as well as current hurdles that must be overcome for wider clinical applications of this promising approach.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Gu, Q., Dillon, C. F., & Burt, V. L. (2010). Prescription drug use continues to increase: U.S. prescription drug data for 2007–2008. NCHS Data Brief, 42, 1–8.

    PubMed  Google Scholar 

  2. Roger, V. L., et al. (2012). Heart disease and stroke statistics–2012 update: a report from the American Heart Association. Circulation, 125(1), e2–e220.

    Article  PubMed  Google Scholar 

  3. Takahashi, K., et al. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 131(5), 861–872.

    Article  PubMed  CAS  Google Scholar 

  4. Yu, J., et al. (2007). Induced pluripotent stem cell lines derived from human somatic cells. Science, 318(5858), 1917–1920.

    Article  PubMed  CAS  Google Scholar 

  5. Thomson, J. A., et al. (1998). Embryonic stem cell lines derived from human blastocysts. Science, 282(5391), 1145–1147.

    Article  PubMed  CAS  Google Scholar 

  6. Park, I. H., et al. (2008). Reprogramming of human somatic cells to pluripotency with defined factors. Nature, 451(7175), 141–146.

    Article  PubMed  CAS  Google Scholar 

  7. Ellison, G. M., et al. (2007). Myocyte death and renewal: modern concepts of cardiac cellular homeostasis. Nature Clinical Practice. Cardiovascular Medicine, 4(Suppl 1), S52–S59.

    Article  PubMed  CAS  Google Scholar 

  8. MacLellan, W. R., & Schneider, M. D. (2000). Genetic dissection of cardiac growth control pathways. Annual Review of Physiology, 62, 289–319.

    Article  PubMed  CAS  Google Scholar 

  9. Nadal-Ginard, B., et al. (2003). A matter of life and death: cardiac myocyte apoptosis and regeneration. The Journal of Clinical Investigation, 111(10), 1457–1459.

    PubMed  CAS  Google Scholar 

  10. Torella, D., et al. (2006). Resident human cardiac stem cells: role in cardiac cellular homeostasis and potential for myocardial regeneration. Nature Clinical Practice. Cardiovascular Medicine, 3(Suppl 1), S8–S13.

    Article  PubMed  CAS  Google Scholar 

  11. Boudoulas, K. D., & Hatzopoulos, A. K. (2009). Cardiac repair and regeneration: the Rubik's cube of cell therapy for heart disease. Disease Models & Mechanisms, 2(7–8), 344–358.

    Article  CAS  Google Scholar 

  12. Habib, M., Caspi, O., & Gepstein, L. (2008). Human embryonic stem cells for cardiomyogenesis. Journal of Molecular and Cellular Cardiology, 45(4), 462–474.

    Article  PubMed  CAS  Google Scholar 

  13. Laflamme, M. A., & Murry, C. E. (2005). Regenerating the heart. Nature Biotechnology, 23(7), 845–856.

    Article  PubMed  CAS  Google Scholar 

  14. Murry, C. E., Field, L. J., & Menasche, P. (2005). Cell-based cardiac repair: reflections at the 10-year point. Circulation, 112(20), 3174–3183.

    Article  PubMed  Google Scholar 

  15. Hyun, I., et al. (2008). New ISSCR guidelines underscore major principles for responsible translational stem cell research. Cell Stem Cell, 3(6), 607–609.

    Article  PubMed  CAS  Google Scholar 

  16. Goldring, C. E., et al. (2011). Assessing the safety of stem cell therapeutics. Cell Stem Cell, 8(6), 618–628.

    Article  PubMed  CAS  Google Scholar 

  17. Lian, Q., et al. (2010). Future perspective of induced pluripotent stem cells for diagnosis, drug screening and treatment of human diseases. Thrombosis and Haemostasis, 104(1), 39–44.

    Article  PubMed  CAS  Google Scholar 

  18. Tanaka, T., et al. (2009). In vitro pharmacologic testing using human induced pluripotent stem cell-derived cardiomyocytes. Biochemical and Biophysical Research Communications, 385(4), 497–502.

    Article  PubMed  CAS  Google Scholar 

  19. Yokoo, N., et al. (2009). The effects of cardioactive drugs on cardiomyocytes derived from human induced pluripotent stem cells. Biochemical and Biophysical Research Communications, 387(3), 482–488.

    Article  PubMed  CAS  Google Scholar 

  20. Kannankeril, P. J., & Roden, D. M. (2007). Drug-induced long QT and torsade de pointes: recent advances. Current Opinion in Cardiology, 22(1), 39–43.

    Article  PubMed  Google Scholar 

  21. Carlsson, L. (2006). In vitro and in vivo models for testing arrhythmogenesis in drugs. Journal of Internal Medicine, 259(1), 70–80.

    Article  PubMed  CAS  Google Scholar 

  22. Thomsen, M. B., et al. (2006). Assessing the proarrhythmic potential of drugs: current status of models and surrogate parameters of torsades de pointes arrhythmias. Pharmacology and Therapeutics, 112(1), 150–170.

    Article  PubMed  CAS  Google Scholar 

  23. Miller, R. A., et al. (2008). Efficient array-based identification of novel cardiac genes through differentiation of mouse ESCs. PLoS One, 3(5), e2176.

    Article  PubMed  Google Scholar 

  24. Cao, F., et al. (2008). Transcriptional and functional profiling of human embryonic stem cell-derived cardiomyocytes. PLoS One, 3(10), e3474.

    Article  PubMed  Google Scholar 

  25. Varlet, I., Collignon, J., & Robertson, E. J. (1997). Nodal expression in the primitive endoderm is required for specification of the anterior axis during mouse gastrulation. Development, 124(5), 1033–1044.

    PubMed  CAS  Google Scholar 

  26. Conlon, F. L., et al. (1994). A primary requirement for nodal in the formation and maintenance of the primitive streak in the mouse. Development, 120(7), 1919–1928.

    PubMed  CAS  Google Scholar 

  27. Ben-Haim, N., et al. (2006). The nodal precursor acting via activin receptors induces mesoderm by maintaining a source of its convertases and BMP4. Developmental Cell, 11(3), 313–323.

    Article  PubMed  CAS  Google Scholar 

  28. Brennan, J., et al. (2001). Nodal signalling in the epiblast patterns the early mouse embryo. Nature, 411(6840), 965–969.

    Article  PubMed  CAS  Google Scholar 

  29. Winnier, G., et al. (1999). Bone morphogenetic protein-4 is required for mesoderm formation and patterning in the mouse. Genes & Development, 9(17), 2105–2116.

    Article  Google Scholar 

  30. Liu, P., et al. (1999). Requirement for Wnt3 in vertebrate axis formation. Nature Genetics, 22(4), 361–365.

    Article  PubMed  CAS  Google Scholar 

  31. Pearce, J. J., & Evans, M. J. (1999). Mml, a mouse Mix-like gene expressed in the primitive streak. Mechanisms of Development, 87(1–2), 189–192.

    Article  PubMed  CAS  Google Scholar 

  32. Wilkinson, D. G., Bhatt, S., & Herrmann, B. G. (1990). Expression pattern of the mouse T gene and its role in mesoderm formation. Nature, 343(6259), 657–659.

    Article  PubMed  CAS  Google Scholar 

  33. Blum, M., et al. (1992). Gastrulation in the mouse: the role of the homeobox gene goosecoid. Cell, 69(7), 1097–1106.

    Article  PubMed  CAS  Google Scholar 

  34. Ciruna, B. G., & Rossant, J. (1999). Expression of the T-box gene Eomesodermin during early mouse development. Mechanisms of Development, 81(1–2), 199–203.

    Article  PubMed  CAS  Google Scholar 

  35. Ema, M., Takahashi, S., & Rossant, J. (2006). Deletion of the selection cassette, but not cis-acting elements, in targeted Flk1-lacZ allele reveals Flk1 expression in multipotent mesodermal progenitors. Blood, 107(1), 111–117.

    Article  PubMed  CAS  Google Scholar 

  36. Takakura, N., et al. (1997). PDGFR alpha expression during mouse embryogenesis: immunolocalization analyzed by whole-mount immunohistostaining using the monoclonal anti-mouse PDGFR alpha antibody APA5. Journal of Histochemistry and Cytochemistry, 45(6), 883–893.

    Article  PubMed  CAS  Google Scholar 

  37. Sakurai, H., et al. (2006). In vitro modeling of paraxial and lateral mesoderm differentiation reveals early reversibility. Stem Cells, 24(3), 575–586.

    Article  PubMed  CAS  Google Scholar 

  38. Tam, P. P., & Behringer, R. R. (1997). Mouse gastrulation: the formation of a mammalian body plan. Mechanisms of Development, 68(1–2), 3–25.

    Article  PubMed  CAS  Google Scholar 

  39. Buckingham, M., Meilhac, S., & Zaffran, S. (2005). Building the mammalian heart from two sources of myocardial cells. Nature Reviews Genetics, 6(11), 826–835.

    Article  PubMed  CAS  Google Scholar 

  40. McKinsey, T. A., Zhang, C. L., & Olson, E. N. (2002). MEF2: a calcium-dependent regulator of cell division, differentiation and death. Trends in Biochemical Sciences, 27(1), 40–47.

    Article  PubMed  CAS  Google Scholar 

  41. Antonini, G., et al. (2000). Natural history of cardiac involvement in myotonic dystrophy: correlation with CTG repeats. Neurology, 55(8), 1207–1209.

    Article  PubMed  CAS  Google Scholar 

  42. Belaguli, N. S., et al. (2000). Cardiac tissue enriched factors serum response factor and GATA-4 are mutual coregulators. Molecular and Cellular Biology, 20(20), 7550–7558.

    Article  PubMed  CAS  Google Scholar 

  43. Wang, Q., et al. (2001). Comparative studies on the expression patterns of three troponin T genes during mouse development. Anatomical Record, 263(1), 72–84.

    Article  PubMed  CAS  Google Scholar 

  44. Hescheler, J., et al. (1997). Embryonic stem cells: a model to study structural and functional properties in cardiomyogenesis. Cardiovascular Research, 36(2), 149–162.

    Article  PubMed  CAS  Google Scholar 

  45. Keller, G. (2005). Embryonic stem cell differentiation: emergence of a new era in biology and medicine. Genes & Development, 19(10), 1129–1155.

    Article  CAS  Google Scholar 

  46. Boheler, K. R., et al. (2005). Cardiomyocytes derived from embryonic stem cells. Methods in Molecular Medicine, 108, 417–435.

    PubMed  Google Scholar 

  47. Boheler, K. R., et al. (2002). Differentiation of pluripotent embryonic stem cells into cardiomyocytes. Circulation Research, 91(3), 189–201.

    Article  PubMed  CAS  Google Scholar 

  48. Takahashi, K., & Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 126(4), 663–676.

    Article  PubMed  CAS  Google Scholar 

  49. Wernig, M., et al. (2007). In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature, 448(7151), 318–324.

    Article  PubMed  CAS  Google Scholar 

  50. Novak, A., et al. (2010). Enhanced reprogramming and cardiac differentiation of human keratinocytes derived from plucked hair follicles, using a single excisable lentivirus. Cellular Reprogramming, 12(6), 665–678.

    Article  PubMed  CAS  Google Scholar 

  51. Haase, A., et al. (2009). Generation of induced pluripotent stem cells from human cord blood. Cell Stem Cell, 5(4), 434–441.

    Article  PubMed  CAS  Google Scholar 

  52. Li, C., et al. (2009). Pluripotency can be rapidly and efficiently induced in human amniotic fluid-derived cells. Human Molecular Genetics, 18(22), 4340–4349.

    Article  PubMed  CAS  Google Scholar 

  53. Jia, F., et al. (2010). A nonviral minicircle vector for deriving human iPS cells. Nature Methods, 7(3), 197–199.

    Article  PubMed  CAS  Google Scholar 

  54. Fusaki, N., et al. (2009). Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proceedings of the Japan Academy. Series B, Physical and Biological Sciences, 85(8), 348–362.

    Article  PubMed  CAS  Google Scholar 

  55. Yu, J., et al. (2009). Human induced pluripotent stem cells free of vector and transgene sequences. Science, 324(5928), 797–801.

    Article  PubMed  CAS  Google Scholar 

  56. Burridge, P. W., et al. (2012). Production of de novo cardiomyocytes: human pluripotent stem cell differentiation and direct reprogramming. Cell Stem Cell, 10(1), 16–28.

    Article  PubMed  CAS  Google Scholar 

  57. Keller, G. M. (1995). In vitro differentiation of embryonic stem cells. Current Opinion in Cell Biology, 7(6), 862–869.

    Article  PubMed  CAS  Google Scholar 

  58. Mummery, C., et al. (2003). Differentiation of human embryonic stem cells to cardiomyocytes: role of coculture with visceral endoderm-like cells. Circulation, 107(21), 2733–2740.

    Article  PubMed  CAS  Google Scholar 

  59. Nakano, T., Kodama, H., & Honjo, T. (1994). Generation of lymphohematopoietic cells from embryonic stem cells in culture. Science, 265(5175), 1098–1101.

    Article  PubMed  CAS  Google Scholar 

  60. Murry, C. E., & Keller, G. (2008). Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development. Cell, 132(4), 661–680.

    Article  PubMed  CAS  Google Scholar 

  61. Nishikawa, S. I., et al. (1998). Progressive lineage analysis by cell sorting and culture identifies FLK1 + VE-cadherin + cells at a diverging point of endothelial and hemopoietic lineages. Development, 125(9), 1747–1757.

    PubMed  CAS  Google Scholar 

  62. Anonymous. (2006). The bitterest pill. Nature, 444(7119), 532–533.

    Article  Google Scholar 

  63. Kola, I., & Landis, J. (2004). Can the pharmaceutical industry reduce attrition rates? Nature Reviews. Drug Discovery, 3(8), 711–715.

    Article  PubMed  CAS  Google Scholar 

  64. Force, T., & Kolaja, K. L. (2011). Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. Nature Reviews. Drug Discovery, 10(2), 111–126.

    Article  PubMed  CAS  Google Scholar 

  65. Lawrence, C. L., et al. (2008). In vitro models of proarrhythmia. British Journal of Pharmacology, 154(7), 1516–1522.

    Article  PubMed  CAS  Google Scholar 

  66. Ma, J., et al. (2011). High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents. American Journal of Physiology - Heart and Circulatory Physiology, 301(5), H2006–H2017.

    Article  PubMed  CAS  Google Scholar 

  67. Zhang, J., et al. (2009). Functional cardiomyocytes derived from human induced pluripotent stem cells. Circulation Research, 104(4), e30–e41.

    Article  PubMed  CAS  Google Scholar 

  68. Braam, S. R., et al. (2010). Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes. Stem Cell Research, 4(2), 107–116.

    Article  PubMed  CAS  Google Scholar 

  69. Chapin, R. E., & Stedman, D. B. (2009). Endless possibilities: stem cells and the vision for toxicology testing in the 21st century. Toxicological Sciences, 112(1), 17–22.

    Article  PubMed  CAS  Google Scholar 

  70. Davila, J. C., et al. (2004). Use and application of stem cells in toxicology. Toxicological Sciences, 79(2), 214–223.

    Article  PubMed  CAS  Google Scholar 

  71. Ebert, A. D., Liang, P., & Wu, J. C. (2012). Induced pluripotent stem cells as a disease modeling and drug screening platform. Journal of Cardiovascular Pharmacology, 60(4), 408–416.

    Article  PubMed  CAS  Google Scholar 

  72. Dick, E., et al. (2010). Evaluating the utility of cardiomyocytes from human pluripotent stem cells for drug screening. Biochemical Society Transactions, 38(4), 1037–1045.

    Article  PubMed  CAS  Google Scholar 

  73. Caspi, O., et al. (2009). In vitro electrophysiological drug testing using human embryonic stem cell derived cardiomyocytes. Stem Cells and Development, 18(1), 161–172.

    Article  PubMed  CAS  Google Scholar 

  74. McNeish, J. (2004). Embryonic stem cells in drug discovery. Nature Reviews. Drug Discovery, 3(1), 70–80.

    Article  PubMed  CAS  Google Scholar 

  75. Pollard, C. E., Valentin, J. P., & Hammond, T. G. (2008). Strategies to reduce the risk of drug-induced QT interval prolongation: a pharmaceutical company perspective. British Journal of Pharmacology, 154(7), 1538–1543.

    Article  PubMed  CAS  Google Scholar 

  76. Brimecombe, J. C., Kirsch, G. E., & Brown, A. M. (2009). Test article concentrations in the hERG assay: losses through the perfusion, solubility and stability. Journal of Pharmacological and Toxicological Methods, 59(1), 29–34.

    Article  PubMed  CAS  Google Scholar 

  77. Lahti, A. L., et al. (2012). Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture. Disease Models & Mechanisms, 5(2), 220–230.

    Article  CAS  Google Scholar 

  78. Chaudhary, K. W., et al. (2006). Embryonic stem cells in predictive cardiotoxicity: laser capture microscopy enables assay development. Toxicological Sciences, 90(1), 149–158.

    Article  PubMed  CAS  Google Scholar 

  79. Mohr, J. C., et al. (2010). The microwell control of embryoid body size in order to regulate cardiac differentiation of human embryonic stem cells. Biomaterials, 31(7), 1885–1893.

    Article  PubMed  CAS  Google Scholar 

  80. Rana, P., et al. (2012). Characterization of human induced pluripotent stem cell derived cardiomyocytes: bioenergetics and utilization in safety screening. Toxicological Sciences, 130(1), 117–131.

    Article  PubMed  CAS  Google Scholar 

  81. Takei, S., et al. (2009). Bone morphogenetic protein-4 promotes induction of cardiomyocytes from human embryonic stem cells in serum-based embryoid body development. American Journal of Physiology - Heart and Circulatory Physiology, 296(6), H1793–H1803.

    Article  PubMed  CAS  Google Scholar 

  82. Reppel, M., et al. (2005). The electrocardiogram of human embryonic stem cell-derived cardiomyocytes. Journal of Electrocardiology, 38(4 Suppl), 166–170.

    Article  PubMed  Google Scholar 

  83. Harmer, A. R., et al. (2008). Optimisation and validation of a medium-throughput electrophysiology-based hNav1.5 assay using IonWorks. Journal of Pharmacological and Toxicological Methods, 57(1), 30–41.

    Article  PubMed  CAS  Google Scholar 

  84. Sanchez-Freire, V., et al. (2012). Microfluidic single-cell real-time PCR for comparative analysis of gene expression patterns. Nature Protocols, 7(5), 829–838.

    Article  PubMed  CAS  Google Scholar 

  85. Muzikant, A. L., & Penland, R. C. (2002). Models for profiling the potential QT prolongation risk of drugs. Current Opinion in Drug Discovery & Development, 5(1), 127–135.

    CAS  Google Scholar 

  86. Meyer, T., et al. (2004). QT-screen: high-throughput cardiac safety pharmacology by extracellular electrophysiology on primary cardiac myocytes. Assay and Drug Development Technologies, 2(5), 507–514.

    Article  PubMed  CAS  Google Scholar 

  87. Sun, N., et al. (2012). Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Science Translational Medicine, 4(130), 130ra47.

    Article  PubMed  Google Scholar 

  88. Cubeddu, L. X. (2003). QT prolongation and fatal arrhythmias: a review of clinical implications and effects of drugs. American Journal of Therapy, 10(6), 452–457.

    Article  Google Scholar 

  89. Drici, M. D., & Clement, N. (2001). Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome. Drug Safety, 24(8), 575–585.

    Article  PubMed  CAS  Google Scholar 

  90. Yang, L., et al. (2008). Human cardiovascular progenitor cells develop from a KDR + embryonic-stem-cell-derived population. Nature, 453(7194), 524–528.

    Article  PubMed  CAS  Google Scholar 

  91. Kiskinis, E., & Eggan, K. (2010). Progress toward the clinical application of patient-specific pluripotent stem cells. The Journal of Clinical Investigation, 120(1), 51–59.

    Article  PubMed  CAS  Google Scholar 

  92. Schulz, T. C., et al. (2007). A large-scale proteomic analysis of human embryonic stem cells. BMC Genomics, 8, 478.

    Article  PubMed  Google Scholar 

  93. Thomas, R. J., et al. (2009). Automated, scalable culture of human embryonic stem cells in feeder-free conditions. Biotechnology and Bioengineering, 102(6), 1636–1644.

    Article  PubMed  CAS  Google Scholar 

  94. Anderson, D., et al. (2007). Transgenic enrichment of cardiomyocytes from human embryonic stem cells. Molecular Therapy, 15(11), 2027–2036.

    Article  PubMed  CAS  Google Scholar 

  95. Huber, I., et al. (2007). Identification and selection of cardiomyocytes during human embryonic stem cell differentiation. The FASEB Journal, 21(10), 2551–2563.

    Article  CAS  Google Scholar 

  96. Xu, X. Q., et al. (2008). Highly enriched cardiomyocytes from human embryonic stem cells. Cytotherapy, 10(4), 376–389.

    Article  PubMed  Google Scholar 

  97. Rajala, K., et al. (2010). A defined and xeno-free culture method enabling the establishment of clinical-grade human embryonic, induced pluripotent and adipose stem cells. PLoS One, 5(4), e10246.

    Article  PubMed  Google Scholar 

  98. Rodriguez-Piza, I., et al. (2010). Reprogramming of human fibroblasts to induced pluripotent stem cells under xeno-free conditions. Stem Cells, 28(1), 36–44.

    PubMed  CAS  Google Scholar 

  99. Narsinh, K. H., et al. (2011). Single cell transcriptional profiling reveals heterogeneity of human induced pluripotent stem cells. The Journal of Clinical Investigation, 121(3), 1217–1221.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We would like to acknowledge the funding support from NIH R01 HL113006, Fondation Leducq 11CVD02, CIRM RB3-05129 (JCW), and AHA Postdoctoral Fellowship (PWB).

Disclosures

None

Author information

Authors and Affiliations

  1. Department of Medicine (Division of Cardiology), Stanford University, 265 Campus Drive G1120B, Stanford, CA, 94305-5454, USA

    Nicholas M. Mordwinkin, Paul W. Burridge & Joseph C. Wu

  2. Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, 265 Campus Drive G1120B, Stanford, CA, 94305-5454, USA

    Nicholas M. Mordwinkin, Paul W. Burridge & Joseph C. Wu

  3. Stanford Cardiovascular Institute, Stanford University, 265 Campus Drive G1120B, Stanford, CA, 94305-5454, USA

    Nicholas M. Mordwinkin, Paul W. Burridge & Joseph C. Wu

Authors
  1. Nicholas M. Mordwinkin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul W. Burridge
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joseph C. Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joseph C. Wu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mordwinkin, N.M., Burridge, P.W. & Wu, J.C. A Review of Human Pluripotent Stem Cell-Derived Cardiomyocytes for High-Throughput Drug Discovery, Cardiotoxicity Screening, and Publication Standards. J. of Cardiovasc. Trans. Res. 6, 22–30 (2013). https://doi.org/10.1007/s12265-012-9423-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12265-012-9423-2

Keywords

Search

Navigation